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Multivessel coronary artery disease
ST-segment elevation myocardial infarctionBackground: Randomized evidence comparing newer-generation drug-eluting stents for multivessel percutane-
ous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) is limited.
We sought to investigate clinical outcomes in STEMI patients undergoing multivessel PCI with thin-strut biode-
gradable polymer sirolimus-eluting stents (BP-SES) versus durable polymer everolimus-eluting stents (DP-EES).
Methods: We performed a subgroup analysis of the BIOSTEMI (NCT02579031) randomized trial, which included
individual patient data from STEMI patients enrolled into the BIOSCIENCE (NCT02579031) study. STEMI patients
randomly allocated to BP-SES or DP-EES were divided into those undergoing multivessel versus culprit lesion-
only PCI. The primary endpoint was target lesion failure (TLF), a composite of cardiac death, target vessel myo-
cardial re-infarction or clinically indicated target lesion revascularization (TLR), within 24 months.
Results: Among 1707 STEMI patients, 145 patients underwent multivessel PCI. At 2 years, TLF occurred in
2 patients (2.8%) treated with BP-SES and 13 patients (18.7%) treated with DP-EES (hazard ratio [HR], 0.14;
95% confidence interval (CI), 0.03–0.61; p = 0.009) in the multivessel PCI group, and in 40 (5.3%) and 61
(8.2%) patients treatedwith BP-SES and DP-EES respectively (HR, 0.64; 95%CI, 0.43–0.96; p=0.03; p for interac-
tion = 0.050) in the culprit lesion-only PCI group. In the multivessel PCI group, the rates of clinically indicated
TLR (0% vs. 12.4%) and target vessel myocardial re-infarction (0% vs. 4.6%) at 2 years were lower in patients
treated with BP-SES compared with DP-EES.
Conclusion: In a subgroup analysis of the BIOSTEMI trial, BP-SESwere associatedwith lower 2-year TLF rates com-
pared to DP-EES in STEMI patients undergoing multivessel PCI.
© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license
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Multivessel coronary artery disease (MVD) is common in patients
with ST-segment elevation myocardial infarction (STEMI) undergoing
primary percutaneous coronary intervention (PCI) [1] and is associated
with worse outcomes compared with single-vessel coronary artery dis-
ease [1,2]. Completemultivessel revascularization by PCI provides supe-
rior long-term clinical outcomes compared to culprit lesion-only PCI in
patients with STEMI and MVD [3,4]. Randomized evidence comparing
differential clinical outcomes between newer-generation drug-elutinger the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ever limited.
Newest-generation thin-strut biodegradable polymer sirolimus-
eluting stents (BP-SES) are superior to second-generation durable poly-
mer everolimus-eluting stents (DP-EES) with respect to target lesion
failure (TLF) at 1 year among patients with STEMI, a difference driven
by a lower risk of ischemia driven target lesion revascularization (TLR)
[5]. Long-term clinical advantages of thin-strut BP-SES over DP-EES
may therefore be anticipated in STEMI patients undergoing multivessel
PCI, considering the beneficial effects of thin-strut BP-SES may accumu-
late with the increasing number of lesions treated. We therefore per-
formed a subgroup analysis of the BIOSTEMI trial to investigate
potential differences in clinical outcomes between thin-strut BP-SES
and DP-EES among STEMI patients undergoing multivessel PCI.
2. Methods
BIOSTEMI (NCT02579031) was an investigator-initiated, prospec-
tive, multicentre trial that randomly assigned STEMI patients in a 1:1
ratio to thin-strut BP-SES or DP-EES [6]. Randomization was stratified
according to the presence or absence of MVD, which was defined as
≥2 coronary stenoses in ≥2 vessels and/or in the left main coronary ar-
tery. In the present subanalysis, MVD patients were further divided
into those undergoing multivessel versus culprit lesion-only PCI.
Multivessel PCI using randomly allocated study stents in all stenoses
was permitted during the index procedure or within 3 months, at the
operator's discretion. The primary endpoint was TLF, a composite ofTable 1
Clinical outcomes at 2 years in multivessel versus culprit lesion-only PCI groups.
Multivessel PCI
BP-SES DP-EES HR
Patients – no. n = 72 n = 73




All-cause death 4 (5.6) 7 (9.7) 0.5
(0.1
Cardiac death 2 (2.8) 5 (7.0) 0.3
(0.0
Myocardial re-infarction 1 (1.5) 5 (7.7) 0.1
(0.0
Target vessel myocardial re-infarction 0 (0.0) 3 (4.6) NA








Target lesion revascularization (any) 0 (0.0) 9 (13.9) NA
Clinically indicated target lesion revascularization 0 (0.0) 8 (12.4) NA




















Definite stent thrombosis 0 (0.0) 2 (3.1) NA
Definite or probable stent thrombosis 0 (0.0) 3 (4.4) NA
Number of events and percentages are reported. HR, hazard ratio; CI, confidence interval. BP-S
eluting stent; PCI, percutaneous coronary intervention.
a Composite of cardiac death, target vessel myocardial re-infarction, and clinically indicated
b Composite of cardiac death, any myocardial re-infarction, or any target vessel revasculariz
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cardiac death, target vessel myocardial re-infarction, or clinically indi-
cated TLR, within 24 months. Secondary endpoints included individual
components of the primary endpoint, all-cause death, myocardial re-
infarction, any revascularization, target vessel failure (TVF) as a com-
posite of cardiac death, myocardial re-infarction or target vessel revas-
cularization, definite stent thrombosis, and definite or probable stent
thrombosis at 2 years. The study protocol was approved by institutional
ethics committees at participating sites and complied with the Declara-
tion of Helsinki. All patients provided written informed consent for
participation.
Consistentwith themain analysis [5],we included individual patient
data from STEMI patients enrolled into BIOSCIENCE (NCT02579031), a
prospective, multicenter, randomized, non-inferiority trial that com-
pared BP-SES and DP-EES with respect to TLF in all-comers patients un-
dergoing percutaneous coronary revascularization [7]. p-values for
main effects of stent type within subgroups were obtained from
Chi-squared, Fisher's exact or Student's t-tests, as appropriate.
p-values for interactions between subgroups and stent types were
calculated using generalized linear, Poisson and logistic models
(mixed-effects for lesion-level). Hazard ratios (HR), 95% confidence
intervals (CI), p-values for main effects and p-values for interactions
were obtained from mixed-effect survival models, in which the trial
identity (BIOSTEMI or BIOSCIENCE) was fitted as random intercept
[8]. We reported time-to-first event for outcomes, and numbers of
patients and Kaplan-Meier estimates of cumulative incidence. Statisti-
cal analyses were conducted using R Studio version 3.5.2 and STATA
version 15.Culprit lesion-only PCI p-Value
for
interaction
(95% CI) p-value BP-SES DP-EES HR (95% CI) p-value
n = 781 n = 774
4
3–0.61)















0.121 27 (3.7) 25 (3.4) 1.07
(0.62–1.85)
0.801 0.118










0.054 47 (6.4) 63 (8.7) 0.73
(0.50–1.07)
0.108 0.185
NA 24 (3.3) 34 (4.7) 0.70
(0.41–1.17)
0.175 NA



























NA 10 (1.3) 12 (1.6) 0.82
(0.36–1.91)
0.651 NA
NA 16 (2.1) 22 (2.9) 0.72
(0.38–1.36)
0.309 NA
ES, biodegradable polymer sirolimus-eluting stent; DP-EES, durable polymer everolimus-
target lesion revascularization (primary endpoint).
ation.
Fig. 1. Time-to-event curves for target lesion failure and its individual components at 2-year follow-up. A, target lesion failure; B, cardiac death; C, target vessel (TV) myocardial re-
infarction; D, clinically indicated target lesion revascularization (TLR). Red lines, biodegradable polymer sirolimus-eluting stent (BP-SES); blue lines, durable polymer everolimus-eluting
stent (DP-EES); solid lines, multivessel percutaneous coronary intervention (PCI); dash lines, culprit lesion-only primary PCI. HR, hazard ratio. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
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Among 1707 STEMI patients enrolled into BIOSCIENCE (n = 407)
and BIOSTEMI (n = 1300) trials, 145 patients underwent multivessel
PCI with BP-SES (n=72) or DP-EES (n=73), of which 45 and 100 pa-
tients were included in BIOSCIENCE and BIOSTEMI trials, respectively.
Among patients who underwent multivessel PCI, the median time
from primary PCI to the staged procedure was 37.3 ± 22.7 days.
Baseline clinical, angiographic and procedural characteristics did not
significantly differ between groups (Supplementary Tables 1 and 2).
The 2-year TLF risk was numerically higher among patients undergoing
multivessel PCI as compared to culprit lesion-only PCI (10.7% vs. 6.7%;
p = 0.089) (Supplementary Table 3). At 2 years, TLF occurred in 2 pa-
tients (cumulative incidence, 2.8%) treated with BP-SES and 13 patients
(18.7%) treatedwith DP-EES (HR, 0.14; 95% CI, 0.03–0.61; p=0.009) in
the multivessel PCI group, and in 40 (5.3%) and 61 (8.2%) patients
treated with BP-SES and DP-EES respectively (HR, 0.64; 95%
CI, 0.43–0.96; p = 0.03; p for interaction = 0.050) in the culprit
lesion-only PCI group (Table 1; Fig. 1). In themultivessel PCI group, dif-
ferences in 2-yearTLF ratesbetweenBP-SES andDP-EESwere consistent
among patients included in BIOSCIENCE and BIOSTEMI trials (Supple-
mentary Table 4). The rates of cardiac death (2.8% vs. 7.0%), target vessel
myocardial re-infarction (0% vs. 4.6%) and clinically indicated TLR (0% vs.
12.4%) at 2 yearswere lower among patients undergoingmultivessel PCI3
with thin-strut BP-SES as compared to those treated with DP-EES
(Table 1; Fig. 1). Patient-oriented composite endpoints including cardiac
death or myocardial re-infarction (4.3% vs. 14.3%; HR, 0.27; 95% CI,
0.08–1.00; p= 0.049), all-cause death, myocardial re-infarction or any
revascularization (11.2% vs. 26.6%; HR, 0.37; 95% CI, 0.16–0.85; p =
0.019), and TVF (7.1% vs. 23.0%; HR, 0.28; 95% CI, 0.10–0.76; p=0.013)
at 2 years of follow-upwere significantly lower amongpatients undergo-
ing multivessel PCI with BP-SES compared to DP-EES (Table 1).
4. Discussion
In a subgroup analysis of the BIOSTEMI randomized trial, we found
significant differences in 2-year rates of TLF favoring thin-strut BP-SES
overDP-EES amongSTEMI patients undergoingmultivessel PCI. This dif-
ference was mainly caused by higher rates of major adverse cardiac
events, including cardiac death, target vessel myocardial re-infarction,
and ischemia driven TLR, among STEMI patients undergoingmultivessel
PCI with DP-EES as compared to thin-strut BP-SES. Overall, there was a
borderline significant treatment interaction suggesting incremental
clinical benefits with thin-strut BP-SES over DP-EES with respect to the
2-year TLF risk in patients with STEMI undergoing multivessel PCI. To
the best of our knowledge, the present is the first study suggesting dif-
ferential clinical outcomes between newer-generation DES in patients
with STEMI undergoing multivessel PCI. Thick-strut biodegradable
J.F. Iglesias, O. Muller, S. Losdat et al. International Journal of Cardiology xxx (xxxx) xxxpolymer DES have shown similar safety and efficacy outcomes at 1 year
of follow-up comparedwith second-generation durable polymer-based
DES among STEMI patients undergoingmultivessel PCI [9]. Our findings
suggest that most recent DES iterations combining thinner stent plat-
forms with biodegradable polymers may provide incremental clinical
benefits compared to second-generation polymer-based DES in STEMI
patients undergoingmultivessel PCI by reducing the riskof repeat revas-
cularization. The observed lower TLR rates among patients treated with
thin-strut BP-SES compared with contemporary newer-generation DES
are consistent with the results from a recent large-scale, real-life, all-
comers registry [10]. The present study suggests particular clinical ben-
efits from thin-strut BP-SES in patients with STEMI undergoing
multivessel PCI, in which the lower risk of TLR with thin-strut BP-SES
over DP-EES may accumulate with the number of stents used. The po-
tential mechanism by which thin-strut BP-SES reduce TLF compared to
DP-EES in STEMI patients undergoing multivessel PCI remains unclear
and warrants further dedicated studies. In addition to strut thickness
and polymer characteristics, BP-SES and DP-EES also differ in terms of
stent platform geometry, polymer composition, thickness or distribu-
tion, and antiproliferative drug composition or elution kinetics, all of
which may potentially impact on clinical outcomes.
5. Limitations
The present analysis is underpowered to assess clinical differences
between BP-SES and DP-EES due to the small sample size and these
findings are therefore hypothesis-generating. Future properly powered
studies are warranted to investigate the comparative effects of thin-
strut BP-SES versus DP-EES in STEMI patients undergoing multivessel
PCI. Finally, the results of the present study should be interpreted in
view of higher 2-year rates of ischemia-driven TLR and stent thrombosis
than those observed in previous randomized clinical trials including
STEMI patients treated with DP-EES [11].
6. Conclusion
In conclusion, in a subgroup analysis of the BIOSTEMI randomized
trial, thin-strut BP-SES were associated with significantly lower TLF
rates at 2 years of follow-up compared with DP-EES in patients with
STEMI undergoing multivessel PCI.
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